Endurant Capital Management’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-168,609
Closed -$10.8M 91
2018
Q4
$10.8M Buy
168,609
+70,208
+71% +$5.18M 5.71% 4
2018
Q3
$8.81M Buy
98,401
+27,196
+38% +$2.4M 3.92% 6
2018
Q2
$5.66M Buy
71,205
+39,205
+123% +$3.26M 2.45% 15
2018
Q1
$2.85M Sell
32,000
-5,800
-15% -$557K 1.07% 28
2017
Q4
$3.94M Buy
37,800
+21,500
+132% +$2.43M 1.21% 35
2017
Q3
$2.38M Sell
16,300
-34,900
-68% -$4.75M 0.72% 50
2017
Q2
$6.65M Sell
51,200
-6,300
-11% -$772K 1.88% 24
2017
Q1
$7.16M Buy
57,500
+22,020
+62% +$2.64M 2.3% 16
2016
Q4
$4.11M Buy
35,480
+2,000
+6% +$223K 1.7% 23
2016
Q3
$3.5M Buy
33,480
+10,600
+46% +$1.15M 1.3% 27
2016
Q2
$2.26M Buy
22,880
+8,600
+60% +$890K 0.75% 40
2016
Q1
$1.43M Sell
14,280
-12,400
-46% -$1.28M 0.46% 52
2015
Q4
$3.19M Buy
26,680
+5,580
+26% +$646K 1.07% 34
2015
Q3
$2.28M Buy
21,100
+640
+3% +$79.4K 0.76% 42
2015
Q2
$2.37M Sell
20,460
-9,500
-32% -$1.09M 0.7% 43
2015
Q1
$3.45M Buy
29,960
+14,600
+95% +$1.74M 1.14% 33
2014
Q4
$1.72M Buy
+15,360
New +$1.62M 0.67% 45

Other funds holding CELG

Endurant Capital Management's CELG Position: Q1 2019 in Review

Endurant Capital Management sold out of Celgene Corp (CELG) in Q1 2019, closing a stake of 168,609 shares — an estimated $10.8M sold.

Endurant Capital Management first reported a position in CELG in Q4 2014 and held it in 17 quarters. The position peaked at $10.8M in Q4 2018. 1,389 funds tracked by Wall St. Rank hold CELG as of Q1 2019.

  • Endurant Capital Management reported no remaining Celgene Corp position as of Q1 2019 after selling out during the quarter.
  • Endurant Capital Management sold 168,609 Celgene Corp shares in Q1 2019, an estimated $10.8M.
  • Endurant Capital Management first reported a position in Celgene Corp in Q4 2014 and held it in 17 quarters.
  • Endurant Capital Management's Celgene Corp position peaked at $10.8M in Q4 2018.
  • 1,389 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2019.

Based on Endurant Capital Management's 13F filing for Q1 2019, filed 15 May 2019.